These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39058809)

  • 1. A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.
    Haroon J; Jordan K; Mahdavi K; Rindner E; Becerra S; Surya JR; Zielinski M; Venkatraman V; Goodenowe D; Hofmeister K; Zhang J; Ahlem C; Reading C; Palumbo J; Pourat B; Kuhn T; Jordan S
    Medicine (Baltimore); 2024 Jul; 103(30):e39027. PubMed ID: 39058809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum.
    Jiang J; Zhuo Z; Wang A; Li W; Jiang S; Duan Y; Ren Q; Zhao M; Wang L; Yang S; Awan MUN; Liu Y; Xu J
    Alzheimers Res Ther; 2024 Jul; 16(1):149. PubMed ID: 38961406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
    Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
    Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Longitudinal Cognitive Decline and Alzheimer's Conversion in Mild Cognitive Impairment Patients Based on Plasma Biomarkers.
    Park MK; Ahn J; Kim YJ; Lee JW; Lee JC; Hwang SJ; Kim KC
    Cells; 2024 Jun; 13(13):. PubMed ID: 38994939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tau deposition using
    Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M
    Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.
    Abe K; Shang J; Shi X; Yamashita T; Hishikawa N; Takemoto M; Morihara R; Nakano Y; Ohta Y; Deguchi K; Ikeda M; Ikeda Y; Okamoto K; Shoji M; Takatama M; Kojo M; Kuroda T; Ono K; Kimura N; Matsubara E; Osakada Y; Wakutani Y; Takao Y; Higashi Y; Asada K; Senga T; Lee LJ; Tanaka K
    J Alzheimers Dis; 2020; 73(1):217-227. PubMed ID: 31771070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study.
    Palmqvist S; Hertze J; Minthon L; Wattmo C; Zetterberg H; Blennow K; Londos E; Hansson O
    PLoS One; 2012; 7(6):e38639. PubMed ID: 22761691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
    Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
    Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.